Showing results (1-10 of 367) with videos related to
Sort By:
Pageof 37
Arthritis Research & Therapy|September 20, 2005
Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDsJames M Scheiman, A Mark FendrickThe American Journal of Medicine|May 20, 2003
Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysisUri Ladabaum, James M Scheiman, A Mark FendrickThe American Journal of Gastroenterology|December 21, 2002
Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United StatesUri Ladabaum, A Mark Fendrick, David Glidden, et al.Arthritis and Rheumatism|April 5, 2002
Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysisA Mark Fendrick, Rajesh R Bandekar, Michael E Chernew, et al.Academic Radiology|June 18, 2003
Making cost-effectiveness analyses clinically relevant: the effect of provider expertise and biliary disease prevalence on the economic comparison of alternative diagnostic strategiesRuth C Carlos, James M Scheiman, Hero K Hussain, et al.The American Journal of Managed Care|February 15, 2020
Expand predeductible coverage without increasing premiums or deductiblesA Mark FendrickThe American Journal of Managed Care|December 3, 2002
Cost-effective use of NSAIDs: issues pertinent to coxib use in managed careA Mark FendrickCleveland Clinic Journal of Medicine|June 28, 2002
Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathyA Mark FendrickThe American Journal of Managed Care|April 27, 2011
A pharmacoeconomic perspective on stroke prevention in atrial fibrillationA Mark FendrickJournal of Clinical Gastroenterology|November 3, 2015
NSAID-induced Gastrointestinal Injury: A Focused Update for CliniciansJames M ScheimanPageof 37